In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...

The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates (ADCs), a class of treatments that are designed to deliver potent che ...

In recent years, scientists have discovered that some chemotherapy drugs not only kill cancer cells directly, but at least in some patients, mysteriously also trigger their immune system to attack the ...

In cancer patients with brain metastases and type 2 diabetes, those using GLP-1 drugs had a 37% lower risk of death over 3 years. Significant mortality benefits were linked to semaglutide and ...

Cipla USA has recalled over 400 cartons of Nilotinib Capsules used to treat blood cancers after they failed to meet specifications, according to the U.S. Food and Drug Administration, which classified ...

Over the past decade, however, a wave of technological advances has begun to expand the druggable proteome. These include covalent inhibitors (such as sotorasib), chemical proteomics, and AI-enabled ...

A US-based subsidiary of drugmaker Cipla is recalling over 400 cartons of generic anti-cancer medication due to a ...

A phase III trial found that combining giredestrant with Pfizer’s Ibrance did not significantly slow disease progression compared with standard ...

Cipla recalls over 400 cartons of Nilotinib cancer medication in the U.S. due to manufacturing specification issues, USFDA reports.

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has ​signed an exclusive global licensing deal ‌with ...